基于血液学毒性调整辅助化疗剂量:PANTHER研究肥胖患者进一步结果
PANTHER是一项多中心开放标签随机III期试验,比较 tailoring 剂量密集表柔比星/环磷酰胺和 tailoring 多西他赛(tDD)与标准间隔5-FU/E/C和多西他赛。本次二次分析回顾性探索剂量调整概念,发现tDD组无复发生存(BCRFS)不随累积表柔比星剂量变化(P=0.495),且肥胖患者(BMI≥30)相比非肥胖者BCRFS改善(HR=0.51,95%CI 0.30-0.89,P=0.02);tDD仅在肥胖患者中相比标准治疗改善BCRFS(HR=0.49,95%CI 0.26-0.90,P=0.022),非肥胖者无显著差异(HR=0.79,95%CI 0.60-1.04,P=0.089),交互作用P=0.175;各表柔比星剂量水平或BMI组间毒性无差异。
要点
- tDD组BCRFS不随累积表柔比星剂量变化(P=0.495)。
- 肥胖患者tDD相比标准治疗改善BCRFS(HR=0.49,95%CI 0.26-0.90,P=0.022)。
- 非肥胖患者tDD与标准治疗BCRFS无显著差异(HR=0.79,95%CI 0.60-1.04,P=0.089)。
核心结论
- 剂量调整是可行策略,可能改善肥胖患者结局而不增加毒性,需进一步临床研究。
研究设计与样本
- PANTHER为多中心、开放标签、随机III期试验,比较tDD与标准间隔5-FU/E/C和D。
- 本次为二次分析,回顾性探索剂量调整概念,主要终点BCRFS,主要疗效分析已发表。
主要发现
- tDD组BCRFS不随累积表柔比星剂量变化(P=0.495)。
- tDD组肥胖患者(BMI≥30)相比非肥胖者(BMI<30)BCRFS改善(HR=0.51,95%CI 0.30-0.89,P=0.02)。
- tDD相比标准治疗仅在肥胖患者中改善BCRFS(HR=0.49,95%CI 0.26-0.90,P=0.022),非肥胖者无显著差异(HR=0.79,95%CI 0.60-1.04,P=0.089)。
- 交互作用P=0.175,差异未达正式统计学显著。
- 各表柔比星剂量水平或BMI组间毒性无差异。
临床怎么用
- 对肥胖乳腺癌患者,基于血液学毒性的剂量调整(tDD)可能改善BCRFS且不增加毒性。
- 非肥胖患者中tDD相比标准治疗未显示显著BCRFS获益。
局限性
- 本次为回顾性探索性二次分析,交互作用未达统计学显著(P=0.175)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could partly be explained by the significant interpatient variability in pharmacokinetics which cannot be captured by dosing according to body surface area. Consequently, tailored dosing was prospectively evaluated in the PANTHER trial. PATIENTS AND METHODS: PANTHER is a multicenter, open-label, randomized phase III trial which compared tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD) with standard interval 5-fluorouracil/E/C and D. The primary end point was BCRFS and the primary efficacy analysis has been previously published. In this secondary analysis, we aimed to retrospectively explore the concept of dose tailoring. Our two hypotheses were that BCRFS would not vary depending on the cumulative administered epirubicin dose; and that dose tailoring would lead to appropriate dosing and improved outcomes for obese patients, who are known to have worse prognosis and increased toxicity after DD ACT. RESULTS: Patients treated with tDD had similar BCRFS regardless of the cumulative epirubicin dose (P = 0.495), while obese patients in this group [body mass index (BMI) ≥30] had improved BCRFS compared with nonobese ones (BMI <30) [hazard ratio (HR) = 0.51, 95% confidence interval (CI) 0.30-0.89, P = 0.02]. Moreover, tDD was associated with improved BCRFS compared with standard treatment only in obese patients (HR = 0.49, 95% CI 0.26-0.90, P = 0.022) but not in nonobese ones (HR = 0.79, 95% CI 0.60-1.04, P = 0.089). The differences were not formally statistically significant (P for interaction 0.175). There were no differences in terms of toxicity across the epirubicin dose levels or the BMI groups. CONCLUSIONS: Dose tailoring is a feasible strategy that can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies. CLINICALTRIALS.GOV IDENTIFIER: NCT00798070.
引用
- Matikas A, Foukakis T, Moebus V, et al. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2019. PMID: 30357310. doi:10.1093/annonc/mdy475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。